about
Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flowGlycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaquesMatrix-specific suppression of integrin activation in shear stress signaling.Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins.Single particle tracking of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type-1 repeats) molecules on endothelial von Willebrand factor stringsEpitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha.Selection of phages that inhibit vWF interaction with collagen under both static and flow conditions.Identification of peptides, selected by phage display technology, that inhibit von Willebrand factor binding to collagen.A probe for capture and Fe3+-induced conformational change of lactoferrin selected from phage displayed peptide libraries.Immobilised peptide displaying phages as affinity ligands. Purification of lactoferrin from defatted milk.Macroporous monolithic gels, cryogels, with immobilized phages from phage-display library as a new platform for fast development of affinity adsorbent capable of target capture from crude feeds.Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates.New model of transient strain-dependent autoimmune thrombocytopenia in mice immunized with rat platelets.How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects?ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.[Determination of the ADAMTS13 antigen and its activity in TTP patients and carriers].Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization.Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor--collagen interaction in baboons.The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons.ADAMTS13 in health and disease.Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.Pig-to-baboon liver xenoperfusion utilizing GalTKO.hCD46 pigs and glycoprotein Ib blockade.Chromato-panning: an efficient new mode of identifying suitable ligands from phage display libraries.The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice.ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura.Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy.Recirculated normal platelets adhere to surfaces coated with plasma from patients with immune thrombocytopenia.Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.Apparent heterogeneity in the pIII-peptide fusion protein in single-phage clones isolated from peptide libraries.Structural determinants within platelet glycoprotein Ibalpha involved in its binding to von Willebrand factor.Identification of a small molecule that modulates platelet glycoprotein Ib-von Willebrand factor interactionTranscription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function.An integrated fragment based screening approach for the discovery of small molecule modulators of the VWF-GPIbα interaction.Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.Affinity comparison of p3 and p8 peptide displaying bacteriophages using surface plasmon resonance.The GPIbalpha-thrombin interaction: far from crystal clear.
P50
Q24305071-5AB89AA8-8E24-4500-9B45-785E339E396BQ28219804-B66D921A-8645-4222-8AEF-3589DBDE77E3Q30441401-AD27094F-4580-4D8D-AD57-1AB55A1BAC51Q30487560-E18CD0C2-3A83-466D-AD4A-67E41679A268Q30575673-6FB6DD0C-9545-41F9-90A3-2F034BD68A8DQ30691871-96725E2B-2CDA-4863-B614-395C39A37315Q31004737-7BA5F114-A9F0-45C8-A973-13383ECD9652Q31963780-02E400F5-AC7E-46CB-AB61-7CFDEAA007F9Q33206956-7309C45E-7375-45A4-AD3F-4B1477520EA3Q33224940-9A50965F-7DC4-42D3-B691-1C6EC40B2664Q33294672-C68F9CF2-9537-4695-9DB5-EFCF1FA0D1A5Q33332419-9645DC01-78F2-4988-888F-CC3BBDB2E1AEQ33358570-A7AFA472-3C04-4E0D-8CFB-125F7E587175Q33365472-925F0158-0DB4-4874-922F-BFB76DBAA414Q33371177-E9A92F3B-1952-4A51-9C73-415A8773407FQ33371656-BA121170-4243-4435-A3D9-85F0633B3500Q33375720-0EC2823B-2726-4B42-A05F-C9458F5381A2Q33377683-87341FD4-66F5-43A7-8D2E-3C814A74A920Q33381445-311F11D4-DC3F-4385-9C85-E71FCA63719BQ33384900-115C3AF3-5CCF-453F-AD46-FF3A2707D973Q33386400-A7F20678-7914-4EAB-B251-ECDD8111F1CFQ33390150-6DFBA65E-0886-42E5-8B3A-52AE2023207DQ33390171-916F7B9A-7124-4335-A0C0-BC10F44F3E6DQ33402641-CE32C16F-A518-4303-9087-7CFA96A69C5CQ33413932-7991D069-3EAB-4F29-9280-605C326DCBC2Q33418927-D5C7676D-7D6D-4256-9B9E-FDCE6F47BFA8Q33418985-C0EBCF8C-70D2-4A1F-9D2D-8B5CECB5E1D3Q33427651-31CD61EF-C0C3-4EF0-A15D-2EC99FDA64D2Q33437847-BE3C412E-721E-4001-B3FB-174EBE8F0A99Q33439797-1860E825-73C9-4D6E-B398-282B8003EB12Q33498968-9733CD90-7F23-4C1C-9BAB-F8D7C080F4E9Q33773324-3A51DEC2-DEA5-45B6-915A-63BFBD42972DQ33943278-BC049E46-2C73-4F43-A21B-67FE4FEB15A4Q34115554-704C9518-1ACC-4FC4-BEF1-249EB59AE151Q34122627-425F9EBB-47C2-4B67-B603-C46AAED1950EQ34374101-AA2167BE-5ED4-4B60-A3E2-1E0B6886CCD7Q34448727-96F4B24F-21D2-41C6-B57E-6346A5B24452Q34512070-8555E418-39F8-4BFC-9A21-6C3A24DF6535Q35002487-5A147AD3-0FF5-49E5-9343-12D229138837Q35628260-8F611E4F-D63A-469D-B1C6-333BD0A7196C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hans Deckmyn
@ast
Hans Deckmyn
@en
Hans Deckmyn
@es
Hans Deckmyn
@nl
Hans Deckmyn
@sl
type
label
Hans Deckmyn
@ast
Hans Deckmyn
@en
Hans Deckmyn
@es
Hans Deckmyn
@nl
Hans Deckmyn
@sl
prefLabel
Hans Deckmyn
@ast
Hans Deckmyn
@en
Hans Deckmyn
@es
Hans Deckmyn
@nl
Hans Deckmyn
@sl
P1053
L-9434-2015
P106
P21
P31
P3829
P3835
hans-deckmyn3
P496
0000-0003-3952-5501